About Pocket Naloxone
Pocket Naloxone is a Healthcare company based in Bethesda (United States) founded in 2019 by Ashanthi Mathai and Kathryn Bowsher. FDA-approved devices for opioid overdose management are developed. Pocket Naloxone has raised $6.16 million across 1 funding round. The company has 3 employees. Its chief executive, as recorded, is Ashanthi Mathai. Pocket Naloxone offers products and services including NaxSwab OTC. Its focus areas include Life Sciences, Toxicology, Medical Devices and Drug Testing Device. Its legal entity is Pocket Naloxone Corp. Its competitors include Celero Systems, Labb and Oral Cube.
Company details
Pocket Naloxone was founded in 2019 and is based in Bethesda, United States. Medical devices approved by the FDA are developed by the company for managing opioid overdoses. A platform is provided that includes Naloxone Hydrochloride, which functions as an antidote to reverse opioid effects and prevent deaths. Operations focus on healthcare solutions in the opioid crisis sector.
- Headquarters Bethesda, United States
- Employees 3
- Founders Ashanthi Mathai, Kathryn Bowsher
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pocketnaloxone.com
- Social LinkedIn
- Legal Name Pocket Naloxone Corp.
- Total Equity Funding$6.16M (USD)
in 1 rounds
- Latest Funding Round$6.16M (USD), Series A
Mar 2021
- Employee Count3
Products & Services of Pocket Naloxone
Pocket Naloxone offers a comprehensive portfolio of products and services, including NaxSwab OTC.
Nasal swab for rapid Naloxone administration to reverse opioid overdoses.
Funding Insights of Pocket Naloxone
Pocket Naloxone has successfully raised a total of $6.16M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.16 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.16M
- Total Rounds 1
- Last Round Series A — $6.16M
- First Round $6.16M
(Mar 2021)
All 1 funding rounds of Pocket Naloxone with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $6.16M | Series A | – | – | – |
People of Pocket Naloxone
2 people are tracked at Pocket Naloxone (2 in leadership); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Ashanthi Mathai | Co-Founder & CEO | Leadership |
Kathryn Bowsher | Co-Founder | Leadership |
Complete people profiles for Pocket Naloxone
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pocket Naloxone
2 dated milestones of Pocket Naloxone across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Pocket Naloxone is founded.
- Funding First funding round of $6.2M.
Competitors of Pocket Naloxone
Pocket Naloxone has 3 listed competitors in our database. They include Celero Systems, Labb and Oral Cube.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celerosystems.com | 2017 | Lincoln, United States | An ingestible device for detecting opioid overdoses is developed. | |||
| labb.com | 2017 | Portsmouth, United States | Mobile app for efficient drug testing and rapid results via various specimen types. | |||
| oralcube.com | 2014 | Salt Lake, United States | Provides comprehensive drug and alcohol testing devices for healthcare providers and clinics. |
Detailed competitors of Pocket Naloxone
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Toxicology
3 companies that operate in the same segment as Pocket Naloxone (Toxicology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | |||
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | |||
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pocket Naloxone
Pocket Naloxone was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Pocket Naloxone is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
Ashanthi Mathai is the CEO of Pocket Naloxone, as recorded in our data. They have also founded this company.
Pocket Naloxone is a funded company, having raised a total of $6.16M across 1 funding round to date. The company's 1st funding round was a Series A of $6.16M, raised on Mar 2021.
Pocket Naloxone has 3 employees.
Pocket Naloxone was founded in 2019 and is based in Bethesda, United States. Medical devices approved by the FDA are developed by the company for managing opioid overdoses. A platform is provided that includes Naloxone Hydrochloride, which functions as an antidote to reverse opioid effects and prevent deaths. Operations focus on healthcare solutions in the opioid crisis sector.
Pocket Naloxone's top competitors include Celero Systems, Labb and Oral Cube.
Pocket Naloxone offers NaxSwab OTC.
Pocket Naloxone operates through Pocket Naloxone Corp..